Cargando…

IL-17A Damages the Blood–Retinal Barrier through Activating the Janus Kinase 1 Pathway

Blood–retinal barrier (BRB) dysfunction underlies macular oedema in many sight-threatening conditions, including diabetic macular oedema, neovascular age-related macular degeneration and uveoretinitis. Inflammation plays an important role in BRB dysfunction. This study aimed to understand the role o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Byrne, Eimear M., Llorián-Salvador, María, Tang, Miao, Margariti, Andriana, Chen, Mei, Xu, Heping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301352/ https://www.ncbi.nlm.nih.gov/pubmed/34356895 http://dx.doi.org/10.3390/biomedicines9070831

Ejemplares similares

Tofacitinib Ameliorates Retinal Vascular Leakage in a Murine Model of Diabetic Retinopathy with Type 2 Diabetes
por: Byrne, Eimear M., et al.
Publicado: (2021)

Complement activation contributes to subretinal fibrosis through the induction of epithelial-to-mesenchymal transition (EMT) in retinal pigment epithelial cells
por: Llorián-Salvador, María, et al.
Publicado: (2022)

VEGF-B Is an Autocrine Gliotrophic Factor for Müller Cells under Pathologic Conditions
por: Llorián-Salvador, María, et al.
Publicado: (2020)

Minocycline Inhibits Microglial Activation and Improves Visual Function in a Chronic Model of Age-Related Retinal Degeneration
por: Du, Xuan, et al.
Publicado: (2022)

The Janus kinases (Jaks)
por: Yamaoka, Kunihiro, et al.
Publicado: (2004)

Janus Kinases in Leukemia
por: Raivola, Juuli, et al.
Publicado: (2021)

Immune Cells in Subretinal Wound Healing and Fibrosis
por: Szczepan, Manon, et al.
Publicado: (2022)

Inhibiting ex-vivo Th17 responses in Ankylosing Spondylitis by targeting Janus kinases
por: Hammitzsch, Ariane, et al.
Publicado: (2018)

Itch and Janus Kinase Inhibitors
por: HAN, Yujin, et al.
Publicado: (2023)

Macrophage to myofibroblast transition contributes to subretinal fibrosis secondary to neovascular age-related macular degeneration
por: Little, Karis, et al.
Publicado: (2020)

A novel treatment for psoriatic arthritis: Janus kinase inhibitors
por: Chen, Miao, et al.
Publicado: (2020)

Acneiform Lesions but not Acne after Treatment with Janus Kinase Inhibitors: Diagnosis and Management of Janus Kinase-acne
por: BALLANGER, Fabienne, et al.
Publicado: (2023)

Janus kinase inhibitors: jackpot or potluck?
por: Pavithran, Keechilat, et al.
Publicado: (2012)

Janus Kinase Inhibitors and Cell Therapy
por: Assal, Amer, et al.
Publicado: (2021)

IL-17A Enhances Retinal Neovascularization
por: Taylor, Brooklyn E., et al.
Publicado: (2023)

Retinal Pigment Epithelial Cells Express Antimicrobial Peptide Lysozyme – A Novel Mechanism of Innate Immune Defense of the Blood-Retina Barrier
por: Liu, Jian, et al.
Publicado: (2021)

Redox regulation of Janus kinase: The elephant in the room
por: Duhé, Roy J
Publicado: (2013)

The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis
por: Veale, Douglas J, et al.
Publicado: (2019)

Clinical significance of Janus Kinase inhibitor selectivity
por: Choy, Ernest H
Publicado: (2019)

Clinical significance of Janus Kinase inhibitor selectivity
por: Choy, Ernest H
Publicado: (2019)

Janus kinase inhibitors for the therapy of atopic dermatitis
por: Traidl, Stephan, et al.
Publicado: (2021)

Role of Janus Kinase Inhibitors in Therapy of Psoriasis
por: Słuczanowska-Głąbowska, Sylwia, et al.
Publicado: (2021)

Janus kinase inhibitors in autoimmune bullous diseases
por: Huang, Dawei, et al.
Publicado: (2023)

Structural basis of Janus kinase trans-activation
por: Caveney, Nathanael A., et al.
Publicado: (2023)

Direct reprogramming of adult cells: avoiding the pluripotent state
por: Kelaini, Sophia, et al.
Publicado: (2014)

A Two-Stage Laser-Induced Mouse Model of Subretinal Fibrosis Secondary to Choroidal Neovascularization
por: Little, Karis, et al.
Publicado: (2020)

“Small” Intestinal Immunopathology Plays a “Big” Role in Lethal Cytokine Release Syndrome, and Its Modulation by Interferon-γ, IL-17A, and a Janus Kinase Inhibitor
por: Kale, Shiv D., et al.
Publicado: (2020)

Breakdown of the Blood–Retinal Barrier
por: Vinores, S.A.
Publicado: (2010)

Responses of Multipotent Retinal Stem Cells to IL-1β, IL-18, or IL-17
por: Chen, Shida, et al.
Publicado: (2015)

Novel mechanism of cytokine-induced disruption of epithelial barriers: Janus kinase and protein kinase D-dependent downregulation of junction protein expression
por: Naydenov, Nayden G., et al.
Publicado: (2013)

Intestinal ischemia-reperfusion induces the release of IL-17A to regulate cell inflammation, apoptosis and barrier damage
por: Xiao, Li, et al.
Publicado: (2022)

The Janus Face of Death Receptor Signaling during Tumor Immunoediting
por: O’ Reilly, Eimear, et al.
Publicado: (2016)

Interleukin 17A: a Janus-faced regulator of osteoporosis
por: Scheffler, J. M., et al.
Publicado: (2020)

Peripheral Blood Mononuclear Cells from Patients with Type 1 Diabetes and Diabetic Retinopathy Produce Higher Levels of IL-17A, IL-10 and IL-6 and Lower Levels of IFN-γ—A Pilot Study
por: Obasanmi, Gideon, et al.
Publicado: (2023)

Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL- 12
Publicado: (1995)

Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors
por: Knight, Emily A., et al.
Publicado: (2015)

The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease
por: De Vries, L.C.S., et al.
Publicado: (2017)

Role of janus kinase inhibitors in the treatment of alopecia areata
por: Triyangkulsri, Korn, et al.
Publicado: (2018)

Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies
por: Hammitzsch, Ariane, et al.
Publicado: (2020)

Targeting the Janus Kinase Family in Autoimmune Skin Diseases
por: Howell, Michael D., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ia0a6b4o5op8jmg8uu4utv81cu